{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:23:39Z","timestamp":1792657419566,"version":"4.5.0"},"reference-count":34,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Neurol Disord"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>There is no standardized treatment for acquired amyloid polyneuropathy (AAP) in domino liver transplant (DLT) recipients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>Our objective is to analyze the efficacy and safety of patisiran for the treatment of AAP in DLT recipients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>We performed a postauthorization prospective longitudinal study of DLT recipients with AAP who received patisiran treatment for 22\u2009months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The primary endpoint was change in the Neuropathy Impairment Scale (NIS) from baseline. Other assessments included neurophysiologic study, quantitative sensory testing, 10\u2009m walking test, and quality of life and disability questionnaires. As safety parameters we analyzed evidence of graft rejection, immunosuppression levels, and renal and cardiac adverse effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Four patients were recruited. The mean NIS at baseline was 8.5\u2009\u00b1\u20092.08. All patients presented clinical improvement after 22\u2009months of treatment, with a mean NIS of 4.75\u2009\u00b1\u20092.27\u2009points. The mean change from baseline in the NIS was \u22123.75\u2009\u00b1\u20090.71 (95% CI: \u22120.47 to 7.97). The use of patisiran was not associated with cardiovascular or renal side effects. No patient presented relevant changes in immunosuppression levels or graft rejection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our study suggests that patisiran may improve neurological manifestations in DLT recipients with AAP, producing no relevant adverse effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17562864251396030","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T13:26:57Z","timestamp":1765373217000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of patisiran for the treatment of acquired amyloid polyneuropathy in domino liver transplant recipients"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8797-3371","authenticated-orcid":false,"given":"Velina","family":"Nedkova-Hristova","sequence":"first","affiliation":[{"name":"Neuromuscular Unit, Neurology Department, Bellvitge University Hospital-IDIBELL, L\u2019Hospitalet de Llobregat, Barcelona, Spain"},{"name":"Multidisciplinary Unit of Familial Amyloidosis, Bellvitge University Hospital-IDIBELL, L\u2019Hospitalet de Llobregat, Barcelona, Spain"},{"name":"Department of Clinical Sciences, Facultat de Medicina i Ci\u00e8ncies de la Salut, Universitat de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Donadeu","sequence":"additional","affiliation":[{"name":"Laboratory of Nephrology and Transplantation, Vall d\u2019Hebron Research Institute, Vall d\u2019Hebron University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Baliellas","sequence":"additional","affiliation":[{"name":"Multidisciplinary Unit of Familial Amyloidosis, Bellvitge University Hospital-IDIBELL, L\u2019Hospitalet de Llobregat, Barcelona, Spain"},{"name":"Liver Transplantation Unit, Bellvitge University Hospital-IDIBELL, L\u2019Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Gonz\u00e1lez-Costello","sequence":"additional","affiliation":[{"name":"Multidisciplinary Unit of Familial Amyloidosis, Bellvitge University Hospital-IDIBELL, L\u2019Hospitalet de Llobregat, Barcelona, Spain"},{"name":"Advanced Heart Failure and Transplantation Unit, Cardiology Department, Bellvitge University Hospital-IDIBELL, L\u2019Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Llad\u00f3","sequence":"additional","affiliation":[{"name":"Multidisciplinary Unit of Familial Amyloidosis, Bellvitge University Hospital-IDIBELL, L\u2019Hospitalet de Llobregat, Barcelona, Spain"},{"name":"Liver Transplantation Unit, Bellvitge University Hospital-IDIBELL, L\u2019Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Gonz\u00e1lez-Vilatarsana","sequence":"additional","affiliation":[{"name":"Multidisciplinary Unit of Familial Amyloidosis, Bellvitge University Hospital-IDIBELL, L\u2019Hospitalet de Llobregat, Barcelona, Spain"},{"name":"Liver Transplantation Unit, Bellvitge University Hospital-IDIBELL, L\u2019Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mios\u00e9s","family":"Morales de la Prida","sequence":"additional","affiliation":[{"name":"Neuromuscular Unit, Neurology Department, Bellvitge University Hospital-IDIBELL, L\u2019Hospitalet de Llobregat, Barcelona, Spain"},{"name":"Multidisciplinary Unit of Familial Amyloidosis, Bellvitge University Hospital-IDIBELL, L\u2019Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7782-2473","authenticated-orcid":false,"given":"Valentina","family":"V\u00e9lez-Santamar\u00eda","sequence":"additional","affiliation":[{"name":"Neuromuscular Unit, Neurology Department, Bellvitge University Hospital-IDIBELL, L\u2019Hospitalet de Llobregat, Barcelona, Spain"},{"name":"Multidisciplinary Unit of Familial Amyloidosis, Bellvitge University Hospital-IDIBELL, L\u2019Hospitalet de Llobregat, Barcelona, Spain"},{"name":"Neurometabolic Diseases Group, Bellvitge Biomedical Research Institute, L\u2019Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol","family":"Bestard","sequence":"additional","affiliation":[{"name":"Laboratory of Nephrology and Transplantation, Vall d\u2019Hebron Research Institute, Vall d\u2019Hebron University Hospital, Barcelona, Spain"},{"name":"Kidney Transplant Unit, Nephrology Department, Vall d\u2019Hebron University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1170-2676","authenticated-orcid":false,"given":"Carlos","family":"Casasnovas","sequence":"additional","affiliation":[{"name":"Neuromuscular Unit, Neurology Department, Bellvitge University Hospital-IDIBELL, Carrer de la Feixa Llarga, s\/n, L\u2019Hospitalet de Llobregat, Barcelona 08907, Spain"},{"name":"Multidisciplinary Unit of Familial Amyloidosis, Bellvitge University Hospital-IDIBELL, L\u2019Hospitalet de Llobregat, Barcelona, Spain"},{"name":"Neurometabolic Diseases Group, Bellvitge Biomedical Research Institute, L\u2019Hospitalet de Llobregat, Barcelona, Spain"},{"name":"Biomedical Research Network Center in Rare Diseases, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09688-0"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2021-327909"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1242815"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.06.004"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23521"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.283815"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182661eb1"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716793"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.18688"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716153"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2022.2091985"},{"key":"e_1_3_5_13_2","first-page":"16","article-title":"Risk of developing de novo amyloid deposits and induced polyneuropathy in FAP domino liver recipients [abstract]","volume":"16","author":"Adams D","year":"2009","unstructured":"Adams D, Lacroix C, Antonini T, et al. Risk of developing de novo amyloid deposits and induced polyneuropathy in FAP domino liver recipients [abstract]. Eur J Neurol 2009; 16(Suppl. 13): 16\u201354.","journal-title":"Eur J Neurol"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2007.00516.x"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/lt.21928"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/lt.22174"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12378"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.3109\/13506129.2014.885894"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0000000000000110"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v9.i3.126"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2015.4715"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/cjp2.36"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14822"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2022.10454"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-024-00621-w"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12256"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu589"},{"key":"e_1_3_5_28_2","unstructured":"Familial amyloidotic polyneuropathy world transplant registry | domino liver transplant registry www.fapwtr.org (2024)."},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-024-07494-9"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.4631"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-12950-3"},{"key":"e_1_3_5_32_2","unstructured":"Agreement of the Pharmacotherapeutic Committee for the Comprehensive Public Use Health System of Catalonia (CFT-SISCAT) of CatSalut on the use of tafamidis inotersen and patisiran for the treatment of polyneuropathy due to hereditary transthyretin amyloidosis https:\/\/catsalut.gencat.cat\/web\/.content\/minisite\/catsalut\/proveidors_professionals\/medicaments_farmacia\/harmonitzacio\/informes\/_compartits\/amiloidosi-polineuropatia\/acord-CFT-SISCAT-tafamidis-inotersen-patisiran-ATTRh.pdf (2024)."},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01960-9"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.17009"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409134"}],"container-title":["Therapeutic Advances in Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864251396030","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562864251396030","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864251396030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T17:29:49Z","timestamp":1769362189000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562864251396030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":34,"alternative-id":["10.1177\/17562864251396030"],"URL":"https:\/\/doi.org\/10.1177\/17562864251396030","relation":{},"ISSN":["1756-2864","1756-2864"],"issn-type":[{"value":"1756-2864","type":"print"},{"value":"1756-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"article-number":"17562864251396030"}}